Latest News and Press Releases

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course...

VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3...

ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP...

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis...

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE-101 IND-Enabling Studies...